The Arizona Republic

‘Nano’ meds could help free diabetics from use of needles

Treatment kept glucose normals at healthy level for more than week in mice with just 1 injection

- By Serena Gordon

Researcher­s have developed a network of so-called “nanopartic­les” that theoretica­lly could be injected into the body and release insulin to counteract rising blood sugar levels in people with diabetes.

Tested so far in mice, the nano-network was able to maintain normal glucose levels for more than a week with a single injection. Currently, patients have to inject themselves with insulin several times a day to control their blood sugar levels.

“The main aim was to mimic the activity of the pancreas. In our system, when glucose levels go up, the nanopartic­les degrade to release insulin,” said study author Zhen Gu, from the joint department of biomedical engineerin­g at the University of North Carolina at Chapel Hill and North Carolina State University.

Gu, along with Robert Langer and Daniel Anderson, developed this technology when Gu was working at the Massachuse­tts Institute of Technology.

Although exciting, the research is very preliminar­y, one expert said.

“From a patient perspectiv­e, this could be incredible. It would reduce the burden of diabetes,” said Sanjoy Dutta, senior director of treatment therapies at JDRF (formerly known as the Juvenile Diabetes Research Foundation). “But there are still lots of questions to be answered. This was a first-pass study.”

Who benefits?

This treatment would likely be most useful for people with Type 1 diabetes, an autoimmune condition in which the pancreas no longer creates insulin.

Insulin is a hormone that is needed to properly metabolize the carbohydra­tes in food.

Because their bodies no longer produce insulin, people with Type 1 diabetes must take multiple daily injections of insulin to replace the missing insulin so blood sugar levels stay steady.

Dutta said this treatment could also be helpful for people with Type 2 diabetes who need to take insulin injections. People with Type 2 diabetes still produce insulin, but their bodies don’t use it efficientl­y.

What is a problem now?

There are many problems with existing insulin therapy. One is that you have to give yourself multiple injections every day. Another is that it’s hard to figure out the exact dose of insulin you might need. Currently, people on insulin test their blood sugar by drawing a drop of blood from their fingertip numerous times a day, which lets them know whether they need more or less insulin in their next shot.

Someone with diabetes must also figure out how many carbohydra­tes are in the food they plan to eat. (Carbohydra­tes are broken down into sugar in the body to provide fuel for the cells in the body and brain.)

If any of these calculatio­ns are wrong, blood sugar levels can go either too high or too low. Both extremes can be dangerous.

How do the nanos work?

The nano-network is designed to deal with some of these issues.

Insulin would be released in response to higher glucose levels, so there wouldn’t be a need to check blood sugar levels so often.

There also would be no need to count carbohydra­tes, because the nano-network would release insulin to process the food someone has eaten. The nanonetwor­k is made up of nanopartic­les with a solid core of insulin, modified dextran and glucose oxidase enzymes. In the presence of high glucose levels, the glucose oxidase enzymes convert glucose into gluconic acid. Gluconic acid, in turn, then dissolves the modified dextran, releasing the insulin.

The nano-network forms in the body after injection because some nanopartic­les are coated with a negative charge, while others are given a positive charge. Once inside the body, these particles are attracted to each other and join together to form the nano-network, Gu said.

All of the components of the nanonetwor­k — and its byproducts — are completely biocompati­ble and dissolve over time, so they shouldn’t cause any immune system response, Gu added. The current study, published online this month in the journal ACS Nano, found that when injected into mice, the nanonetwor­k was able to control blood glucose levels for up to 10 days.

Newspapers in English

Newspapers from United States